XVIVO improved its organic growth to 32% compared with the unusually modest 12% level in Q4 2023. In the critical disposable business, the abdominal sector recorded 46% growth, and the thoracic sector recorded 36% growth in Q1. We expect a positive consensus revision and a positive share price reaction to follow.

https://www.redeye.se/research/997331/xvivo-q1-impressive-growth-in-both-thoracic-and-the-abdominal-business?utm_source=finwire&utm_medium=RSS

Redeye